InvestSMART

AFT Pharmaceuticals Limited (ASX:AFP)

ALERT: Price-sensitive ASX Announcement for AFP
Current share price for AFP : $3.140 0.28 (9.79%)+
Announcement
Release
21 May 2026 7:30AM
Price at Release
$2.860
Full Release
download
Summary
The AFT Pharmaceuticals Limited FY26 Annual Report highlights a successful year ending March 31, 2026, with total revenue of $254.7 million. The company reported a profit after tax of $14.08 million, an increase from the previous year. The financial statements indicate strong performance across various segments, particularly in Australia and New Zealand. The report details their joint operation with Hyloris Pharmaceuticals SA for the Maxigesic IV product, which contributed significantly to revenues. AFT's commitment to sustainability is evident from their GHG emissions reporting, setting science-aligned targets for reducing emissions. The report also outlines substantial investments in intangible assets, primarily in product development and patents. Furthermore, AFT plans to enhance climate resilience by collaborating with suppliers to manage emissions and transitioning to hybrid electric vehicles.
Key Points
  • Total revenue for FY26 was $254.7 million.
  • Profit after tax increased to $14.08 million.
  • Significant contributions from joint operations with Hyloris Pharmaceuticals.
  • Focus on sustainability with science-aligned GHG emission targets.
  • Investments in intangible assets, notably in product development.
  • Plans to enhance climate resilience and manage emissions.
  • Transition to hybrid electric vehicles initiated.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.